ClinicalTrials.gg
CompletedNCT01689519coBRIMUpdated May 2, 2022Results posted

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

A Phase 3 interventional study of Placebo and Vemurafenib in Malignant Melanoma, sponsored by Hoffmann-La Roche. Completed at 156 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
495
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing cobimetinib in Melanoma — 3 open to participants now, 6 under way, 1 of them phase 3. cobimetinib · Melanoma.

Enrollment
Largest of 27
495 · median 45
Started
2013
with 1 other
Phase 3
3 of 27
none open now
Registered
2nd of 27
by date
Lead sponsor
5 of 27
Hoffmann-La Roche

Among the 27 studies testing cobimetinib in Melanoma, this one has the largest enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 2nd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 27 studies testing cobimetinib in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cobimetinib

cobimetinib: first FDA approval 2015 (COTELLIC), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing cobimetinib in Melanoma, or all of them as a file.
02

Study summary

To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma, as measured by progression-free survival (PFS), assessed by the study site investigator.

03

Conditions studied

  • Malignant Melanoma

Browse trials for

Keywords

  • Zelboraf
  • vemurafenib
  • RG7204
  • PLX4032
  • Genentech MEK inhibitor
  • Genentech BRAF inhibitor
  • Roche MEK inhibitor
  • Roche BRAF inhibitor
  • RO5185426
  • metastatic melanoma
  • BRAF positive melanoma
  • BRAF mutant melanoma
  • advanced melanoma
  • Genentech RAF inhibitor
  • Roche RAF inhibitor
  • BRAF V600E kinase inhibitor
  • Oncogenic BRAF inhibitor
  • BRAF kinase inhibitor
  • GDC-0973
  • XL518
  • melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with confirmed melanoma, either unresectable stage IIIc or stage IV melanoma, as defined by the American Joint Committee on Cancer 7th edition. Unresectability of stage IIIc disease must have confirmation from a surgical oncologist
  • Participants must be naïve to treatment for locally advanced unresectable or metastatic disease (ie, no prior systemic anti-cancer therapy for advanced disease; stage IIIc and IV). Prior immunotherapy (including ipilimumab) is allowed
  • Documentation of BRAF V600 mutation-positive status in melanoma tumor tissue (archival or newly obtained tumor samples) using the cobas 4800 BRAF V600 mutation test
  • per v1.1
  • Eastern Clinical Oncology Group performance status of 0 or 1
  • Consent to provide archival for biomarker analyses
  • Consent to undergo tumor for biomarker analyses
  • greater than or equal to (≥) 12 weeks
  • Adequate hematologic and end organ function

Exclusion criteria

Exclusion Criteria:

  • History of prior rapidly accelerated fibrosarcoma or mitogen-activated protein kinase pathway inhibitor treatment
  • Palliative radiotherapy within 14 days prior to the first dose of study treatment
  • Major surgery or traumatic injury within 14 days prior to first dose of study treatment
  • Active other than melanoma that could potentially interfere with the interpretation of efficacy measures. Participants with a previous malignancy within the past 3 years are excluded except for participants with resected basal cell carcinoma or squamous cell carcinoma of the skin, melanoma in-situ, carcinoma in-situ of the cervix, and carcinoma in-situ of the breast
  • History of or evidence of retinal pathology on ophthalmological examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion, or neovascular macular degeneration
  • Uncontrolled glaucoma with intraocular pressure
  • Serum cholesterol ≥ Grade 2
  • Hypertriglyceridemia ≥ Grade 2
  • Hyperglycemia (fasting) ≥ Grade 2
  • History of cardiac dysfunction
  • Participants with active central nervous system (CNS) lesions (including carcinomatous meningitis) are excluded. However, participants are eligible if:

    1. All known CNS lesions have been treated with stereotactic therapy or surgery, AND
    2. There has been no evidence of clinical and radiographic disease progression in the CNS for ≥ 3 weeks after radiotherapy or surgery
  • Current severe, uncontrolled systemic disease
  • History of malabsorption or other condition that would interfere with absorption of study drugs
  • Pregnant, lactating, or breast feeding women
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
495 participants (actual)

Study arms

  • Active comparator
    Placebo + Vemurafenib

    Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.

    Drug: Placebo · Drug: Vemurafenib

  • Experimental
    Cobimetinib + Vemurafenib

    Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.

    Drug: Vemurafenib · Drug: Cobimetinib

Interventions

  • DrugPlacebo

    Placebo supplied as tablets

  • Vemurafenib supplied as tablets

    Also known as: RO518426

  • Cobimetinib supplied as tablets

    Also known as: GDC-0973, RO5514041, XL518

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator using Response Evaluation Criteria in Solid Tumors v1.1, or death from any cause, whichever came first. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.

    Time frame: Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from randomization until the date of death from any cause.

    Time frame: Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)

  2. Percentage of Participants With an Objective Response

    An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart. Responses were determined by Response Evaluation Criteria in Solid Tumors v1.1. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter of target lesions.

    Time frame: Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)

  3. Duration of Response

    Duration of response was defined as the time from first occurrence of a documented confirmed objective response until the time of disease progression, as determined by investigator review of tumor assessments using Response Evaluation Criteria in Solid Tumors v1.1 or death from any cause during the study. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.

    Time frame: Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)

07

Results

Posted Oct 30, 2015

Participant flow

Intent to Treat
Participant flow — Intent to Treat
MilestoneCobimetinib + VemurafenibPlacebo + Vemurafenib
Started247248
Completed00
Not completed247248
Withdrew: Death157167
Withdrew: Lost to follow-up48
Withdrew: Other24
Withdrew: Physician decision41
Withdrew: Study terminated by spon6sor5948
Withdrew: Withdrawal by subject2120
Safety Population
Participant flow — Safety Population
MilestoneCobimetinib + VemurafenibPlacebo + Vemurafenib
Started248245
Completed00
Not completed248245
Withdrew: Death158165
Withdrew: Lost to follow-up48
Withdrew: Other24
Withdrew: Physician decision41
Withdrew: Study terminated by sponsor6047
Withdrew: Withdrawal by subject2020

Outcome measures

PrimaryProgression-free Survival

Progression-free survival was defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator using Response Evaluation Criteria in Solid Tumors v1.1, or death from any cause, whichever came first. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.

Time frame:
Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Reported as:
Median · Months
Progression-free Survival
MonthsCobimetinib + VemurafenibPlacebo + Vemurafenib
Primary Analysis: 9 May 20149.90 (9.00 to NA)6.20 (5.55 to 7.39)
Post hoc Efficacy Analysis: 16 January 201512.30 (9.50 to 13.40)7.20 (5.60 to 7.50)
Extended 5-Year Analysis: 21 July 201912.60 (9.50 to 14.80)7.20 (5.60 to 7.50)
Statistical analysis
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Log Rank · p = 0.0001 (The analysis was stratified by geographic region and metastasis classification (disease stage).) · Hazard ratio (hr): 0.51 · 95% CI 0.39 to 0.68
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Log Rank · p = <0.0001 (The analysis was stratified by geographic region and metastasis classification (disease stage).) · Hazard ratio (hr): 0.58 · 95% CI 0.46 to 0.72
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Log Rank · p = <0.0001 (The analysis was stratified by geographic region and metastasis classification (disease stage).) · Hazard ratio (hr): 0.65 · 95% CI 0.53 to 0.79
SecondaryOverall Survival

Overall survival was defined as the time from randomization until the date of death from any cause.

Time frame:
Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Reported as:
Median · Months
Overall Survival
MonthsCobimetinib + VemurafenibPlacebo + Vemurafenib
Primary Analysis 9 May 2014NA (NA to NA)NA (NA to NA)
Post hoc Analysis 16 January 2015NA (20.70 to NA)17.00 (15.00 to NA)
Final Analysis 28 August 201522.30 (20.3 to NA)17.40 (15.00 to 19.8)
Extended 5-year Analysis 21 July 201922.50 (20.30 to 28.80)17.40 (15.00 to 19.80)
Statistical analysis
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Log Rank · p = 0.0463 (The analysis was stratified by geographic region and metastasis classification (disease stage).) · Hazard ratio (hr): 0.645 · 95% CI 0.42 to 1.00
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Log Rank · p = 0.0034 (The analysis was stratified by geographic region and metastasis classification (disease stage).) · Hazard ratio (hr): 0.65 · 95% CI 0.49 to 0.87
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Log Rank · p = 0.0050 (The analysis was stratified by geographic region and metastasis classification (disease stage).) · Hazard ratio (hr): 0.70 · 95% CI 0.55 to 0.90
SecondaryPercentage of Participants With an Objective Response

An objective response was defined as a complete response or a partial response determined on two consecutive occasions ≥ 4 weeks apart. Responses were determined by Response Evaluation Criteria in Solid Tumors v1.1. A complete response was defined as the disappearance of all target lesions or the disappearance of all non-target lesions and normalization of tumor marker level. A partial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of the longest diameter of target lesions.

Time frame:
Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With an Objective Response
Percentage of participantsCobimetinib + VemurafenibPlacebo + Vemurafenib
Primary Analysis: 9 May 201467.60 (61.39 to 73.41)44.80 (38.46 to 51.18)
Post hoc Efficacy Analysis: 16 January 201569.60 (63.50 to 75.30)50.00 (43.60 to 56.40)
Extended 5-Year Analysis: 21 July 201969.60 (63.49 to 75.31)49.60 (43.21 to 55.99)
Statistical analysis
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Chi-squared · p = <0.0001 · Mean difference (final values): 22.85 · 95% CI 14.13 to 31.58
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Chi-squared · p = <0.0001 · Mean difference (final values): 19.6 · 95% CI 11.0 to 28.3
  • Cobimetinib + Vemurafenib vs Placebo + Vemurafenib · Chi-squared · p = <0.0001 · Mean difference (final values): 20.00 · 95% CI 11.40 to 28.70
SecondaryDuration of Response

Duration of response was defined as the time from first occurrence of a documented confirmed objective response until the time of disease progression, as determined by investigator review of tumor assessments using Response Evaluation Criteria in Solid Tumors v1.1 or death from any cause during the study. Disease progression was defined as: (1) at least a 20% increase in the sum (the increase in the sum must be at least 5 mm) of diameters of target lesions, taking as reference the smallest sum during the study; (2) unequivocal progression of existing non-target lesions; or (3) the appearance of 1 or more new lesions.

Time frame:
Baseline to the 21 July 2019 data cut-off (up to 7 years, 6 months)
Reported as:
Median · Months
Duration of Response
MonthsCobimetinib + VemurafenibPlacebo + Vemurafenib
Primary Analysis: 9 May 2014NA (9.30 to NA)7.29 (5.78 to NA)
Extended 5-Year Analysis: 21 July 201914.65 (12.90 to 19.30)9.23 (7.50 to 12.90)

Adverse events

Collected over Adverse events were collected from the time of each participant's randomization into the study until their last visit until 28 days after the last dose of study drug and during extended 5-year efficacy and safety follow-up analyses (Safety data cut-off: July 2019; up to 7 years, 6 months).. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cobimetinib + Vemurafenib160/247 (64.8%)105/248 (42.3%)239/248 (96.4%)
Placebo + Vemurafenib164/248 (66.1%)71/245 (29%)236/245 (96.3%)
Most frequent serious events
Showing 10 of 180
Most frequent serious events
EventCobimetinib + VemurafenibPlacebo + Vemurafenib
PYREXIAGeneral disorders7/2483/245
PNEUMONIAInfections and infestations6/2483/245
DEHYDRATIONMetabolism and nutrition disorders6/2480/245
PERICARDIAL EFFUSIONCardiac disorders0/2484/245
KERATOACANTHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2484/245
ATRIAL FIBRILLATIONCardiac disorders4/2481/245
ALANINE AMINOTRANSFERASE INCREASEDInvestigations4/2482/245
RASHSkin and subcutaneous tissue disorders4/2482/245
ERYSIPELASInfections and infestations1/2483/245
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders0/2483/245
Most frequent other events
Showing 10 of 70
Most frequent other events
EventCobimetinib + VemurafenibPlacebo + Vemurafenib
DIARRHOEAGastrointestinal disorders151/24884/245
NAUSEAGastrointestinal disorders108/24867/245
ARTHRALGIAMusculoskeletal and connective tissue disorders96/248105/245
RASHSkin and subcutaneous tissue disorders101/24897/245
FATIGUEGeneral disorders93/24883/245
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations90/24810/245
PHOTOSENSITIVITY REACTIONSkin and subcutaneous tissue disorders86/24848/245
PYREXIAGeneral disorders77/24860/245
ALOPECIASkin and subcutaneous tissue disorders42/24875/245
HYPERKERATOSISSkin and subcutaneous tissue disorders31/24874/245

Baseline characteristics

Intent-to-treat population: All randomized participants, regardless of whether or not study treatment was received.

Age, Categorical
Age, Categorical(Participants)Cobimetinib + VemurafenibPlacebo + VemurafenibTotal
<=18 years000
Between 18 and 65 years183179362
>=65 years6469133
Age, Continuous
Age, Continuous(Years)Cobimetinib + VemurafenibPlacebo + VemurafenibTotal
Mean54.9 ± 14.055.3 ± 13.855.1 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Cobimetinib + VemurafenibPlacebo + VemurafenibTotal
Female101108209
Male146140286
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Count of Participants)Cobimetinib + VemurafenibPlacebo + VemurafenibTotal
Asian101
More than one race112
Native Hawaiian or other Pacific Islande011
Black or African American000
White227235462
Unknown or Not Reported16925
Other224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Count of Participants)Cobimetinib + VemurafenibPlacebo + VemurafenibTotal
Hispanic or Latino141226
Not Hispanic or Latino213223436
Not Stated161026
Unknown437
08

Study locations

156 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • The Angeles Clinic and Research Institute - W LA Office
    Los Angeles, California 90025, United States
  • University of California Davis Health System
    Sacramento, California 95817, United States
  • Sutter Pacific Medical Foundation
    Santa Rosa, California 95403, United States
  • University Of Colorado
    Aurora, Colorado 80045, United States
  • Florida Cancer Specialists - Broadway
    Fort Myers, Florida 33901, United States
  • Mount Sinai Medical Center
    Miami Beach, Florida 33140, United States
  • Orlando Health Inc.
    Orlando, Florida 32806, United States
  • Northwestern Center For Clinical Research
    Chicago, Illinois 60611, United States
  • Uni of Kansas Medical Center; Dept of Neurology
    Kansas City, Kansas 66160-7314, United States
  • U of L - Physicians Pulmonology; Dept of Neuroradiology and Dept of Diagnostic Radiology
    Louisville, Kentucky 40202, United States
  • Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology
    Saint Louis, Missouri 63108, United States
  • Dartmouth-Hitchcock Medical Center; Department of Medicine
    Lebanon, New Hampshire 03756, United States
  • Novant Health Oncology Specialists
    Winston-Salem, North Carolina 27103, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • St. Luke's University Health network
    Bethlehem, Pennsylvania 18015, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15261, United States
  • Rhode Island Hospital; Investigational Services
    Providence, Rhode Island 2903, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • Lake Macquarie Private Hospital
    Gateshead, New South Wales 2290, Australia
  • Lismore Base Hospital; Cancer Care & Haematology Unit
    Lismore, New South Wales 2480, Australia
  • Melanoma Institute Australia
    North Sydney, New South Wales 2060, Australia
  • Princess Alexandra Hospital
    Woolloongabba, New South Wales 2050, Australia
  • Royal Darwin Hospital
    Casuarina, Northern Territory 0811, Australia
  • Greenslopes Private Hospital
    Greenslopes, Queensland 4120, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Royal Adelaide Hospital; Hepatology
    Adelaide, South Australia 5000, Australia
  • Ashford Cancer Centre
    Ashford SA, South Australia 5035, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Launceston General Hospital; Gastroenterology Research
    Launceston, Tasmania 7250, Australia
  • Peninsula and South Eastern Haematology and Oncology Group
    Frankston, Victoria 3199, Australia
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • Peter MacCallum Cancer Centre-East Melbourne
    Melbourne, Victoria 3000, Australia
  • The Alfred Hospital
    Prahan, Victoria 3181, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Ordensklinikum Linz Elisabethinen
    Linz, 4020, Austria
  • Landesklinikum St. Pölten
    St. Pölten, 3100, Austria
  • Medizinische Universität Wien
    Wien, 1090, Austria
  • Institut Jules Bordet; Department of Medical Oncology
    Bruxelles, 1000, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • Jessa Zkh (Campus Virga Jesse)
    Hasselt, 3500, Belgium
  • CHU Sart-Tilman
    Liège, 4000, Belgium
  • AZ Delta (Campus Rumbeke)
    Roeselare, 8800, Belgium
  • BC Cancer Agency Vancouver Island Cancer Centre
    Victoria, British Columbia V8R 6V5, Canada
  • Juravinski Cancer Clinic; Department of Oncology
    Hamilton, Ontario L8V 5C2, Canada
  • The Ottawa Hospital Cancer Center; General Campus
    Ottawa, Ontario K1H 1C4, Canada
  • Toronto Sunnybrook Hospital
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Hospital; Department of Med Oncology
    Toronto, Ontario M5G 2M9, Canada
  • London Health Sciences Centre · Victoria Hospital;Department of Pediatrics
    London, Quebec N6A 4G5, Canada
  • McGill University Health Centre/Glen Site / Royal Victoria Hospital
    Montréal, Quebec H2W 1S6, Canada
  • Masarykuv onkologicky ustav
    Brno, 656 53, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Fakultní nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • Multiscan s.r.o.
    Pardubice, 532 03, Czechia
  • Nemocnice Na Bulovce
    Prague, 180 01, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha, 100 34, Czechia
  • Fakultni nemocnice Motol; Neurologicka klinika
    Praha, 150 06, Czechia
  • Groupe Hospitalier Saint André - Hôpital Saint André
    Bordeaux, 33075, France
  • Hôpital Ambroise Paré - Boulogne-Billancourt; Respiratory
    Boulogne Billancourt, 92104, France
  • CHU Clermont Ferrand - Hôpital d'Estaing
    Clermont Ferrand cedex 1, 63003, France
  • CHU de Dijon - Hopital le Bocage
    Dijon, 21000, France
  • Centre Hospitalier Universitaire de Grenoble - Albert Michallon
    La Tronche, 38700, France
  • Hopital Claude Huriez - CHU Lille
    Lille, 59037, France
  • Hopital de la Timone
    Marseille, 13005, France
  • Hopital Saint Eloi
    Montpellier, 34295, France
  • CHU NANTES - Hôtel Dieu; Pharmacy
    Nantes, 44093, France
  • CHU Nice - Hopital de l'Archet 2
    Nice, 06202, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • Hopital Robert Debre; DERMATOLOGIE
    Reims, 51092, France
  • Centre Eugene Marquis; Service d'oncologie
    Rennes, 35042, France
  • St. Josef-Hospital; Studienambulanz
    Bochum, 44791, Germany
  • Elbekliniken Buxtehude GmbH
    Buxtehude, 21614, Germany
  • Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
    Dresden, 01307, Germany
  • Helios Klinikum Erfurt
    Erfurt, 99089, Germany
  • Universitätsklinikum Essen
    Essen, 45147, Germany
  • Universitaetsklinikum Freiburg
    Freiburg, 79106, Germany
  • SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie
    Gera, 07548, Germany
  • Universitätsmedizin Göttingen
    Göttingen, 37075, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitaetsklinikum Schleswig-Holstein - Campus Kiel; Klinik fuer Allgemeine Innere Medizin
    Kiel, 24105, Germany
  • Universitaetsklinikum Koeln; Hematology/Oncology
    Koeln, 50937, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
    Mainz, 55101, Germany
  • Klinikum Mannheim GmbH Universitätsklinikum
    Mannheim, 68167, Germany
  • Fachklinik Hornheide
    Muenster, 48157, Germany
  • Klinikum der Ludwigs-Maximilians-Universitaet Muenchen
    München, 80337, Germany
  • Universitaetsklinikum Regensburg
    Regensburg, 93053, Germany
  • Universitätsklinikum Tübingen
    Tuebingen, 72076, Germany
  • Universitätsklinikum Wurzburg
    Würzburg, 97080, Germany
  • Orszagos Onkologiai Intezet
    Budapest, 1122, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
    Gyula, 5700, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Pecs, 7624, Hungary
  • Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp.
    Szeged, 6720, Hungary
  • Soroka Medical Center; Oncology Dept
    Beer Sheva, 8410100, Israel

Showing the first 100 of 156 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Barteselli G, Goodman GR, Patel Y, Caro I, Xue C, McCallum S. Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. Drug Saf. 2022 Dec;45(12):1491-1499. doi: 10.1007/s40264-022-01248-2. Epub 2022 Oct 30. PubMed 36310331 ↗
  • Ascierto PA, Dreno B, Larkin J, Ribas A, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Atkinson V, Dutriaux C, Garbe C, Hsu J, Jones S, Li H, McKenna E, Voulgari A, McArthur GA. 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res. 2021 Oct 1;27(19):5225-5235. doi: 10.1158/1078-0432.CCR-21-0809. PubMed 34158360 ↗
  • Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dreno B. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib +/- cobimetinib: a pooled analysis of four clinical trials. J Transl Med. 2020 Aug 3;18(1):294. doi: 10.1186/s12967-020-02458-x. PubMed 32746839 ↗
  • de la Cruz-Merino L, Di Guardo L, Grob JJ, Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR, Gomez-Escobar A, Barteselli G, Eng S, Hsu JJ, Uyei A, Dreno B. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J Transl Med. 2017 Jun 24;15(1):146. doi: 10.1186/s12967-017-1246-0. PubMed 28646893 ↗
  • Dreno B, Ribas A, Larkin J, Ascierto PA, Hauschild A, Thomas L, Grob JJ, Koralek DO, Rooney I, Hsu JJ, McKenna EF, McArthur GA. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol. 2017 May 1;28(5):1137-1144. doi: 10.1093/annonc/mdx040. PubMed 28444112 ↗
  • Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Yan Y, Wongchenko M, Chang I, Hsu JJ, Koralek DO, Rooney I, Ribas A, Larkin J. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30. PubMed 27480103 ↗
  • Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, Mandala M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29. PubMed 25265494 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in May 2014, 16 months.

Results were first posted in Oct 2015, 1 year 5 months after primary completion.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 16 months is below that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2012
First posted
Sep 21, 2012
StartActual
Jan 8, 2013
Primary completionActual
May 9, 2014
CompletionActual
Jul 21, 2019
Results first posted
Oct 30, 2015
Last update
May 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01689519
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 21, 2012
Start date
Jan 8, 2013
Primary completion
May 9, 2014
Completion
Jul 21, 2019
Results posted
Oct 30, 2015
Last update
May 2, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobimetinib

Start the discussion